Physician profile
Jay Shastri
NPI 1477758720
$644.28
in general payments reported to CMS, 2019-2025
14 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.82 · 2023: $185 · 2024: $190 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $625.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $150.00 | 2023-2025 | Velphoro, Velphoro |
| Neurocrine Biosciences, INC. | $114.67 | 2025 | |
| Novartis Pharmaceuticals Corporation | $88.91 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $83.99 | 2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $33.50 | 2023 | |
| Ardelyx, INC. | $33.47 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $30.31 | 2024 | Lokelma, Farxiga |
| Nxstage Medical, INC. | $18.82 | 2022 | |
| Travere Therapeutics, INC. | $16.60 | 2025 | |
| Calliditas Therapeutics US INC. | $15.94 | 2024 | |
| Amgen INC. | $15.33 | 2024 | Parsabiv, Aranesp, Tavneos |
| Vifor Pharma, INC. | $15.15 | 2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $14.52 | 2024 | Jynarque |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Shastri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.